Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928.In 1999, it merged with Hoechst AG to form Aventis.As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
This is a list of manufacturers and suppliers of pharmaceuticals with operations in the United Kingdom.. Note: the activities of the parent companies of many of the companies listed below are not restricted solely to the United Kingdom.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The former Hoechst AG and today's Industriepark Höchst. Hoechst AG (German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999.
In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme had a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products were also sold in 90 countries.
Sanofi published readouts of three phase 3 trials of its tolebrutinib multiple sclerosis (MS) treatment. In the first study, the drug met its primary endpoint of delaying time to onset of ...
Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year. [citation needed] On December 21, 2009, Paris-based (France) Sanofi, the world's fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal.